ERBB2 exon 20 insertions are rare in Brazilian non‐small cell lung cancer. Issue 23 (17th October 2022)

• Record Type: Journal Article
• Authors: de Oliveira Cavagna, Rodrigo; Zaniolo, Beatriz Garbe; de Paula, Flávia Escremim; Berardinelli, Gustavo Noriz; Santana, Iara; da Silva, Eduardo Caetano Albino; Dias, Josiane Mourão; Jacinto, Alexandre Arthur; da Nóbrega Oliveira, Rachid Eduardo Noleto; de Marchi, Pedro; Leal, Letícia Ferro; Reis, Rui Manuel
• Is Part Of: Thoracic cancer. Volume 13:Issue 23(2022)
• Page Start: 3402
• Page End: 3407
• Publication Date: 2022-10-17
• Subjects: Brazil -- ERBB2 -- exon 20 insertions -- non‐small cell lung cancer; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.14605
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: ERBB2 exon 20 insertions may impact the clinical management of lung cancer patients. However, the frequency of ERBB2 exon 20 insertions in lung cancer patients in Brazil is scarce. Here, we analyzed 722 Brazilian non‐small cell lung cancer (NSCLC) patients from Barretos Cancer Hospital that were indicated to require routine lung cancer molecular testing. ERBB2 exon 20 insertions were evaluated by a targeted panel using next‐generation sequencing (NGS). Clinicopathological and molecular data were collected from patient medical records. Among the 722 NSCLC patients, 85.2% had lung adenocarcinomas, 53.9% were male, 66.8% were quitter or current smokers, and 63.2% were diagnosed at an advanced stage of the disease. We identified 0.8% (6/722) of patients who harbored the insertion p.(Tyr772_Ala775dup) at exon 20 of the ERBB2 gene. All ERBB2 mutated patients were diagnosed with lung adenocarcinoma, were never smokers, and wild‐type for EGFR, KRAS, and ALK hotspot alterations. Less than 1% of Brazilian NSCLC patients harbor ERBB2 exon 20 insertions, yet they could benefit in future from the new drugs in development. Abstract : ERBB2 exon 20 insertions are rare in Brazilian patients and mutually exclusive with EGFR, KRAS, and ALK alterations.